[go: up one dir, main page]

PT1152751E - Sistema terapeutico transdermal de desoxipeganina - Google Patents

Sistema terapeutico transdermal de desoxipeganina

Info

Publication number
PT1152751E
PT1152751E PT00914071T PT00914071T PT1152751E PT 1152751 E PT1152751 E PT 1152751E PT 00914071 T PT00914071 T PT 00914071T PT 00914071 T PT00914071 T PT 00914071T PT 1152751 E PT1152751 E PT 1152751E
Authority
PT
Portugal
Prior art keywords
desoxypeganine
weight percent
therapeutic system
transoidal
desoxygeganine
Prior art date
Application number
PT00914071T
Other languages
English (en)
Inventor
Lothar Deurer
Thomas Hille
Moormann Dr Joachim
Original Assignee
Hf Arzneimittelforsch Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hf Arzneimittelforsch Gmbh filed Critical Hf Arzneimittelforsch Gmbh
Publication of PT1152751E publication Critical patent/PT1152751E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
PT00914071T 1999-02-19 2000-02-08 Sistema terapeutico transdermal de desoxipeganina PT1152751E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19906977A DE19906977C1 (de) 1999-02-19 1999-02-19 Desoxypeganin-TTS und seine Verwendung

Publications (1)

Publication Number Publication Date
PT1152751E true PT1152751E (pt) 2005-08-31

Family

ID=7898023

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00914071T PT1152751E (pt) 1999-02-19 2000-02-08 Sistema terapeutico transdermal de desoxipeganina

Country Status (11)

Country Link
US (1) US6558696B1 (pt)
EP (1) EP1152751B1 (pt)
JP (1) JP2002537244A (pt)
KR (1) KR100674768B1 (pt)
AT (1) ATE293442T1 (pt)
AU (1) AU3551900A (pt)
DE (2) DE19906977C1 (pt)
DK (1) DK1152751T3 (pt)
ES (1) ES2241588T3 (pt)
PT (1) PT1152751E (pt)
WO (1) WO2000048579A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit
DE10110953A1 (de) * 2001-03-07 2002-09-19 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Verabreichung von partiellen Dopamin-D2-Agonisten
DE10119863A1 (de) * 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Verwendung von Desoxypeganin zur Behandlung von psychiatrischen oder zerebralen Krankheitserscheinungen
DE10163667B4 (de) * 2001-12-21 2006-10-26 Hf Arzneimittelforschung Gmbh Verwendung von Desoxypeganin zur Behandlung der klinischen Depression
DE10305137A1 (de) * 2003-02-07 2004-08-26 Novosis Ag Transdermale therapeutische Abgabesysteme mit einem Butenolid
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
DE10354893B4 (de) * 2003-11-24 2011-03-10 Hf Arzneimittelforschung Gmbh Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen
US9084803B2 (en) 2007-06-29 2015-07-21 Board Of Trustees Of Northern Illinois University Therapeutic uses of glutathione mimics
US20090082436A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched rivastigmine
KR101317158B1 (ko) 2011-02-18 2013-10-15 조선대학교산학협력단 갈란타민 또는 그의 염을 함유하는 경피흡수제제
US20200163952A1 (en) * 2018-11-26 2020-05-28 Steven Hoffman Compositions and methods for treating nerve agent exposure
AU2020276605A1 (en) 2019-05-14 2022-01-20 Tyme, Inc. Compositions and methods for treating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU605614A1 (ru) * 1971-10-20 1978-05-05 Ордена Трудового Красного Знамени Институт Химии Растительных Веществ Ан Узбекской Сср Антихолинэстеразное средство
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil

Also Published As

Publication number Publication date
EP1152751B1 (de) 2005-04-20
ES2241588T3 (es) 2005-11-01
DE50010108D1 (de) 2005-05-25
KR100674768B1 (ko) 2007-01-25
EP1152751A1 (de) 2001-11-14
DK1152751T3 (da) 2005-08-01
JP2002537244A (ja) 2002-11-05
WO2000048579A1 (de) 2000-08-24
DE19906977C1 (de) 2000-06-15
KR20010102241A (ko) 2001-11-15
ATE293442T1 (de) 2005-05-15
US6558696B1 (en) 2003-05-06
AU3551900A (en) 2000-09-04

Similar Documents

Publication Publication Date Title
PT1152751E (pt) Sistema terapeutico transdermal de desoxipeganina
YU2694A (sh) Transdermalni terapeutski sistem za odavanje galantamina
CA1252361A (en) Transdermal delivery of highly ionized fat soluble drugs
BR0109107A (pt) Usos terapêuticos de mediadores ppar
AU2961802A (en) Absorbing agents and cover layer which is impermeable to active substances and which contains channel-formers or removable protective layer of a transdermal therapeutic system
TW570815B (en) Transdermal therapeutic system (TTS) containing the active substance fentanyl
DE59803647D1 (de) Transdermales therapeutisches system mit haftklebender reservoirschicht und unidirektional elastischer rückschicht
EP1210050B8 (en) Diaper changing apparatus
DK0973497T3 (da) Farmaceutisk bæreanordning, egnet til udlevering af farmaceutiske forbindelser til slimhindeoverflade
HK1041228A1 (zh) 电活动孔
BR9808668A (pt) Suspensão aquosa de microcápsulas compreendendo um material biologicamente ativo, e, processos para preparação de uma suspensão aquosa de microcápsulas aderentes e para aplicação de microcápsulas em um substrato pretendido
CA2372710A1 (en) Laminates containing an active substance for transdermal systems
GB2345246B (en) Transdermal drug delivery system
WO2001068060A3 (de) Stabilisierte übersättigte transdermale therapeutische matrixsysteme
DE50004443D1 (de) Wirkstoffhaltige komposition sowie deren herstellung und verwendung
BR9909486A (pt) Compostos calcilìticos
DE69706070D1 (de) Zubereitung zur perkutanen verabreichung enthaltend 6-amino-5-chloro-1-isopropyl-2-(4-methyl-1-piperazinyl)benzimidazol
DK1143938T3 (da) Transdermalt terapeutisk system med en selvklæbende matrix, der indeholder organiske syreadditionssalte af alkaloider af morphin- eller morphin-type
MXPA02009103A (es) Sistema terapeutico transdermal para la administracion de lerisetron.
DK0379933T3 (da) Superficielt behandlingssystem med indhold af et antineoplastisk aktivstof, især 5-fluoruracil
WO2000064414A3 (de) Feste pharmazeutische formulierungen von säurelabilen protonenpumpenblockern
TR200000005T2 (tr) Sıtmaya karşı ß-alkoksiakrilatlar.
CA2370023A1 (en) Transdermal therapeutic system with a highly effective neuroleptic agent
ES2141548T3 (es) Preparado farmaceutico de superficie estabilizada para su aplicacion sobre la piel.
ES2188021T3 (es) Metodo para evitar el uso indebido de un sistema terapeutico percutaneo.